Publications

1

Jun, 2017

The Challenge of Treating Children with Hepatitis C Virus Infection

 

Authors: Indolfi G, Thorne C, El-Sayed MH, Giaquinto C, Gonzalez-Peralta RP.

Published in: J Pediatr Gastroenterol Nutr. 2017.

Abstract: The development of oral hepatitis C virus (HCV) direct-acting antivirals (DAAs) has revolutionized the therapeutic field. Nowadays, multiple safe and highly effective antiviral regimens are commercially available to treat adults with hepatitis C infection. These new regimens for the first time genuinely raise the prospects of eradicating HCV. Many challenges, however, remain from identifying infected individuals to optimizing treatment and ensuring global access to antiviral therapy to all population groups, including children. Recently, in April 2017, the association of sofosbuvir with ribavirin and the fixed-dose combination sofosbuvir/ledipasvir have been approved by the Food and Drug Administration for treatment of children with chronic HCV infection 12 years of age and older. The only drugs currently approved for children younger than 12 years are pegylated interferon and ribavirin. There are 6 registered ongoing pediatric trials assessing safety and efficacy of DAAs, but their current completion timelines are years away. Herein, we summarize the state of the art of DAAs’ development for adult and children and highlight the crucial importance of overcoming barriers to treating children with HCV.

 

Read

24

Feb, 2017

Qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): is it acceptable to young people living with HIV?

 

Authors: Bernays S, Paparini S, Seeley J, Namukwaya Kihika S, Gibb D, Rhodes T.

Published inBMJ Open. 2017;7(2):e012934

Abstract: A qualitative study of the BREATHER (PENTA 16) randomised clinical trial, which compared virological control of Short Cycle Therapy (SCT) (5 days on: 2 days off ) with continuous efavirenz (EFV)-based antiretroviral therapy (CT) in children and young people (aged 8–24) living with HIV with viral load <50 c/mL to examine adaptation, acceptability and experience of SCT to inform intervention development

Read

27

Dec, 2016

Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand.

 

Published in: European Journal of Clinical Pharmacology, in press.

Read

20

Nov, 2016

Tuberculosis in HIV-infected children in Europe, Thailand and Brazil: paediatric TB-HIV EuroCoord study

 

Authors: Turkova A, Chappell E, Chalermpantmetagul S, et al.

Published in: Int J Tuberc Lung Dis 2016, 20:1448-1456.

Read

11

Nov, 2016

Interventions to improve treatment, retention and survival outcomes for adolescents with perinatal HIV-1 in high- and middle-income countries: Moving on up.

 

Authors: Judd A, Sohn A, Collins J.

Published in: Current Opinion in HIV and AIDS 2016; 11(5): 477-486

Read

8

Nov, 2016

Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project.

 

Published in: BMC Infectious Diseases, in press.

Read

14

Sep, 2016

Higher rates of triple class virologic failure in perinatally HIV-infected teenagers compared to heterosexually infected young adults in Europe. 

 

Authors: Judd A, Lodwick R, Noguera-Julian A, Gibb DM, Butler K, Costagliola D, Sabin C, van Sighem A, Ledergerber B, Torti C, Mocroft A, Podzamczer D, Dorrucci M, De Wit S, Obel N, Dabis F, Cozzi-Lepri A, García F, Brockmeyer NH, Warszawski J, Gonzalez-Tome MI, Mussini C, Touloumi G, Zangerle R, Ghosn J, Castagna A, Fätkenheuer G, Stephan C, Meyer L, Campbell MA, Chene G, Phillips A; Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

Published in: HIV Medicine, in press.

Read

24

Jun, 2016

Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents – a multiregion analysis from Southern Africa, West Africa, and Europe.

 

Authors: Schomaker M, Leroy V, Wolfs T, Technau KG, Renner L, Judd A, et al. on behalf of the IeDEA West and Southern Africa regional collaborations and COHERE in EuroCoord.

Published in: International Journal of Epidemiology – in press.

Read

1

Jun, 2016

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

 

Author: The BREATHER (PENTA 16) Trial Group

Published inLancet HIV. 2016;3(9):e421-430

Abstract: For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare short cycle therapy (5 days on, 2 days off ART) versus continuous therapy (continuous ART).

Read

27

Apr, 2016

High prevalence of herpes simplex virus (HSV)- type 2 co-infection among HIVpositive women in Ukraine, but no increased HIV mother-to-child transmission risk

 

Authors: Aebi-Popp K, Bailey H, Malyuta R, Volokha A, Thorne C.

Published in: BMC Pregnancy Childbirth. 2016;16:94.

Read